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Abstract: Adenosine was defined as a neuromodulator which exerts its action by interaction with specific G-
protein coupled receptor termed adenosine receptors. Adenosine receptors are expressed in several tissues and 
cells of our body and exist as four different subtypes of these receptors: A1, A2A, A2B and A3. In the last years 
significant efforts were made to obtain highly potent and selective ligands for the four adenosine receptors 
subtypes. Both agonists and antagonists were used as pharmacological tools to study therapeutic implications 
of enhancing or blocking the adenosine receptors activity, and some of these compounds have reached clinical 
phases. The pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines (PTPs) represent one of the several templates 
designed as adenosine receptor antagonists. A lot of synthetic work was made on this scaffold in order to 
obtain potent A2A and A3 antagonists. Here were reviewed the synthetic approaches followed by both 
academia and industry to introduce different substituents at different positions of the PTP nucleus, in 
particular at the 2, 5, 7, 8 and 9 positions. Nevertheless PTP derivatives are tricyclic compounds with a high 
molecular weight which exhibit limitations such as poor aqueous solubility and difficult synthetic preparation. 
With the aim to obtain derivatives with the same potency and selectivity of PTP but with better drug-like 
properties, researchers made structural simplification of this scaffold. Replacement of the pyrazole or triazole 
rings of PTP led to the [1,2,4]triazolo[1,5-c]pyrimidine and pyrazolo[3,4-d]pyrimidine derivatives, 
respectively.  Synthetic strategies for these compounds were reported, combined with the SAR profile on the 
adenosine receptors. 
Keywords: pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine, [1,2,4]triazolo[1,5-c]pyrimidine; pyrazolo[3,4-d]pyrimidine; adenosine 
receptors; antagonists; Preladenant.
1. INTRODUCTION 
 Adenosine receptors (ARs) belong to class A of the G 
protein-coupled receptors family. A1, A2A, A2B and A3 ARs 
are the four AR subtypes currently identified. [1] The 
endogenous agonist of these receptors is adenosine, whereas 
the natural psychotropic compound caffeine is a well-known 
exogenous AR antagonist. [1,2] The different distribution of 
the four AR subtypes in cells, tissues and organs of the 
human body, confers to them different physio-pathological 
roles. [2] Potent and selective ligands (i.e. agonists and 
antagonists) at the various ARs are precious pharmacological 
tools, essential to characterize the ARs under physiological 
and pathological conditions. In the last decades, several AR 
antagonists have been reported and some of them were also 
tested in preclinical and clinical studies. [3] One of the most 
important class of AR antagonists are the pyrazolo[4,3-
e][1,2,4]triazolo[1,5-c]pyrimidines (PTP, 1a-b). PTP 
derivatives have been designed principally as A2A and A3 AR 
antagonists (Figure 1). [4] Preladenant (SCH 420814, 2), an 
A2A AR antagonist which possesses a PTP scaffold, has 
reached the phase III clinical trials for the treatment of 
Parkinson’s disease (PD), but failed for lack of efficacy. [5-
8] In order to improve the pharmacokinetic properties of 
PTPs, a molecular simplification approach was applied on 
this complex tricyclic scaffold. The pyrazole ring of PTP 
was eliminated leading to the simplified [1,2,4]triazolo[1,5-
c]pyrimidine (TP, 3) scaffold. [9-14] Another nucleus which 
could be considered as a simplified analog, by removal of 
[1,2,4]triazole ring from PTP scaffold, is the pyrazolo[3,4-
d]pyrimidine (PP, 4) nucleus. [15-21] Both of these classes 
of compounds led to derivatives that behave like adenosine 
receptor antagonists (Figure 2). 
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Figure 1. Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines. 
 
Figure 2. Simplified analogs of the PTP scaffold. 
1.1. Adenosine receptors as drug targets 
 The adenosine receptors are involved in several 
physiological and pathological processes. [2] As GPCR (G 
protein-coupled receptor), A1 and A3 ARs are coupled with 
inhibitory G proteins (Gi), which inhibit adenylyl cyclase 
(AC) reducing the cyclic AMP (cAMP) levels. On the 
contrary, A2A and A2B ARs are coupled with stimulatory G 
proteins (Gs), those that activate AC enhancing the cAMP 
levels. Nevertheless, ARs were found to couple also to other 
G proteins, such as Gq proteins for the A2B and A3 ARs, and 
Golf for the A2A AR in the striatum. [1] In particular, 
activation of the A1 AR could be useful for the treatment of 
cardiac arrhythmias and pain, whereas a block of the 
receptor activity is beneficial in hypertension, heart and 
kidney failure. Coronary artery vasodilation is mediated by 
A2A AR, so agonists are useful as stress agents for 
myocardial perfusion imaging. Regadenoson is an A2A AR 
agonist approved by Food and Drug Administration (FDA) 
for this use. [2] A2A AR is also present in several immune 
cells and its activation leads to multiple anti-inflammatory 
effects. On the other hand, antagonists for the hA2A AR were 
widely studied for the treatment of PD and other 
neurodegenerative disorders. [22] A2B AR is activated by 
high levels of adenosine, which are usually reached under 
pathological conditions such as hypoxia and inflammation. 
[23] In fact, agonists for the A2B AR are studied for the 
involvement in promoting ischemic preconditioning, 
whereas A2B AR antagonists seems to be useful in the 
treatment of asthma and chronic obstructive pulmonary 
disease (COPD). [24] Finally, regarding the last 
characterized among the ARs, the A3 subtype, there are 
evidences of a cardioprotective effect mediated by A3 AR 
agonists. Instead, for other physio-pathological conditions 
involving the A3 AR (e.g. inflammation, cancer and 
glaucoma) conflicting results on a possible beneficial effect 
of agonists or antagonists have been obtained. [25] 
2. PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c] 
PYRIMIDINES 
 In 1993, Gatta et al. have reported the first pyrazolo[4,3-
e][1,2,4]triazolo[1,5-c]pyrimidine derivatives (1a-b) as A2 
adenosine receptor antagonists. [26] At that time, only few 
examples of non-xanthine heterocyclic compounds have 
been found to display antagonistic activity at the A1 or A2A 
ARs. Among these compounds CGS 15943 (5), a 
[1,2,4]triazolo[1,5-c]quinazoline derivative, is a reference 
antagonist for A2A AR but it shows low selectivity for the 
A2A AR versus A1 AR (Figure 3). Gatta et al. explored new 
chemical entities in order to enhance selectivity at the A2A 
AR, such as: imidazo[1,2-c]pyrazolo[4,3-e]pyrimidines, 
pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and 
[1,2,4]triazolo[5,1-i]purines. The pyrazolo[4,3-
e][1,2,4]triazolo[1,5-c]pyrimidine derivatives of this work 
displayed nanomolar affinity at the A2A AR and represented 
a starting point for the development of a new class of potent 
and selective AR antagonists. [26] 
 
Figure 3. Comparison between PTP and [1,2,4]triazolo[1,5-
c]quinazoline derivatives. 
2.1. Chemistry 
 The original work by Gatta et al. [26] applied a synthetic 
approach, reported in Scheme 1, that started from 5-amino-
N1-fluorobenzyl-1H-pyrazole-4-carbonitriles (7), which 
were obtained by reaction of 2-
(ethoxymethylene)malononitrile (6) with 2- or 4-
fluorobenzylhydrazine. [27] Compounds of general formula 
7 were refluxed in triethylorthoformate to give the imidate 
derivatives (8) which, by reacting with benzhydrazide or 2-
furoic acid hydrazide or ethylcarbazate, in ethylene glycol 
monomethylether at reflux, provided the corresponding 4-
imino-4,5-dihydro-pyrazolo[3,4-d]pyrimidine derivatives (9, 
11). The PTP nucleus was finally obtained by refluxing 
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compounds of general formula 9 and 11 in diphenylether. 
The cyclization of derivatives 9 afforded the 7-substituted-
3,7-dihydro-2H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-
c]pyrimidin-2-one nucleus (10), whereas derivatives 11, 
which contain an additional aryl group, provided the 
pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine (12) nucleus 
substituted at both the 7 and the 2 positions. The following 
ring opening of the pyrimidine ring in compounds 12, by 
10% hydrochloric acid, gave the (1H-1,2,4-triazol-5-yl)-1H-
pyrazol-5-amines (13). An alternative and more convenient 
route to obtain compounds with general formula 13 was the 
direct condensation of the appropriated arylhydrazides with 
the aminopyrazoles 7, in diphenylether at reflux. The 
triazolylpyrazoles 13 could be converted in 5-amino-7H-
pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines (15) by 
reaction with cyanamide, or they could be alternatively 
converted to the 6,7-dihydro-5H-pyrazolo[4,3-
e][1,2,4]triazolo[1,5-c]pyrimidin-5-one (14) derivatives by 
reaction with ethyl carbamate.  Finally, in order to obtain 
also the 8-substitued analogs, the appropriated starting 
compound N1-fluorobenzyl-3-amino-4-cianopyrazole (17) 
was obtained by alkylation of the 3-amino-4-cyanopyrazole 
(16) with the 2 or 4-fluorobenzylchloride in N,N-
dimethylformamide (DMF) and using potassium carbonate 
as base. This approach led to a mixture 2:1 of alkylated 
pyrazoles 7 and 17. The desired compounds 17, separated by 
crystallization, were reacted with the corresponding aryl 
hydrazide (benzhydrazide or 2-furoic acid hydrazide) in 
diphenylether under reflux, affording the triazolyl derivatives 
18. As for the previously reported compounds 13, also 
derivatives 18 were converted to the final tricyclic 
compounds (19) by reaction with cyanamide, in N-
methylpyrrolidone at 140-160°C and in the presence of p-
toluensulfonic acid monohydrate. [26] 
 With the aim to extensively explore the 7 position of the 
PTP scaffold, Baraldi et al. searched for a common key 
intermediate that, after alkylation with an appropriate alkyl 
halide, could afford the desired 7-substituted-PTP. [28] This 
intermediate has been identified in 2-furan-2-yl-7H-
pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]-pyrimidin-5-ylamine 
(21), which has been obtained by treatment of the 
corresponding N7-tert-butyl derivative (20, prepared 
following Gatta’s approach) with 99% formic acid at 130 °C 
for 48 h. [29] Unfortunately, this reaction gave a 1:1 mixture 
Scheme 1. Reagents: i: RNHNH2, EtOH; ii: CH(OC2H5)3, rfx, 8h; iii: ArCONH2NH2 or C2H5OCONHNH2, EGME, rfx, 
3h; iv: Ph2O, rfx; v: 10% HCl (aq), rfx, 3h; vi: ArCONH2NH2, Ph2O, rfx; vii: CNNH2, p-toluensulfonic acid, NMP, 140-
160°C; viii: NH2COOC2H5, 210°C, 3h; ix: RCl, DMF, K2CO3, 70°C, 3h. R = 4-fluorobenzyl or 2-fluorobenzyl ; Ar = 2-
furoyl or phenyl. 
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of unsubstituted (21) and N8-tert-butyl (22) derivatives 
(Scheme 2). [30,5] As depicted in Scheme 2, the key 
intermediate 21 could be easily alkylated on the pyrazole 
nitrogen by using anhydrous potassium carbonate as base 
and dry DMF as solvent. The reaction proceeded without 
competition by the amino group at the 5 position of PTP, but 
it afforded two regioisomers, alkylated at the 7- (23) and 8-
positions (24) of the PTP nucleus in a 3:1 ratio, respectively. 
[28] The 7- and 8-alkylated PTP 23-24 were successively 
separated by column chromatography. This synthetic 
approach allows the introduction of different alkyl and 
arylalkyl moieties at the 7 and at the 8 positions, therefore 
both positions could be investigated at the same time. [28] 
 Schering has developed a more convenient synthesis 
(Scheme 3) for the 2-aryl-7H-pyrazolo[4,3-
e][1,2,4]triazolo[1,5-c]-pyrimidin-5-ylamines (28) compared 
to the de-tert-butylation procedure (Scheme 2), which allows 
to obtain large amounts of key intermediate in three steps 
and requires soft purification procedures. [31] The synthesis 
started from the commercially available pyrimidine 
derivative 25, which may be obtained by Vilsmeier’s 
reaction of 2-amino-4,6-dihydroxypyrimidine with POCl3 
and DMF. Compound 25 was reacted with aryl hydrazides 
affording compounds 26. A first cyclization was performed 
by treatment with hydrazine in acetonitrile, obtaining the 
pyrazolo[3,4-d]pyrimidines 27, then, a dehydrative 
cyclization of 27 with N,O-bis(trimethylsilyl)acetamide 
(BSA) at reflux proceeded with concomitant Dimroth 
rearrangement to afford the desired products 28. [31,5] 
Additionally, pyazole alkylation, by using sodium hydride 
instead of potassium carbonate, afforded preferentially the 
N7-alkylated derivatives (29) with small amounts of N8-
alkylated regioisomers.  
 In the same patent also other slightely different synthetic 
approaches were claimed. [31] As depicted in Scheme 4 the 
direct cyclization of compound 25 with hydrazine afforded 
the 4-chloro-1H-pyrazolo[3,4-d]pyrimidin-6-amine (30), 
which could be in turn alkylated with the appropriated 
alkylhalide in the presence of NaH and DMF  to obtain 31. 
As for the alkylation approach used in Scheme 3, also in this 
case, the use of NaH as the base led principally to N1-
alkylated compounds, which correspond to the final N7-
susbtituted PTPs. Subsequent reaction of compounds 31 with 
hydrazine and the appropriated acylchloride, or the direct 
reaction with the appropriated arylhydrazide, gave 
compounds of general formula 33. Finally, the dehydrative 
cyclization of compounds 33 afforded the desired N7-
substituted-PTP derivatives (34). When compound 30 was 
Scheme 2. Reagents: i: HCOOH, 130°C, 48h; ii: RCl, DMF, K2CO3, 100°C, 12h. R = alkyl, arylalkyl. 
Scheme 3. Reagents: i: ArCONHNH2, DIPEA, CH3CN, rt, overnight; ii: NH2NH2.H2O, CH3CN, rfx, 1h.; iii: BSA, HMDS, 
120°C, overnight; iv: RX, NaH, DMF, rt, overnight-24h. Ar = fur-2-yl or thien-2-yl. 
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alkylated with 1-bromo-2-chloroethane, the obtained 
derivative 35 was reacted with tert-butylcarbazate, which 
afforded the 4-hydrazino derivative protected on the primary 
amino group by a Boc (tert-butyloxycarbonyl) moiety (36). 
In this way, compound 36 could be further functionalized on 
the lateral chain at the N7 position (e.g. with 1-aryl-
piperarazines) (compound 37) and the subsequent 
deprotection of the amino moiety with HCl afforded 
compound 32 which then followed the above mentioned 
procedure. 
 All the synthetic pathways hitherto reported for the 
obtainment of 8-substituted-PTP required the separation of 
the two isomers of alkylated pyrazole derivatives. In fact, 
separation occurred at the early stage, such as for the original 
Gatta’s procedure, or at a later stage, such as depicted in 
Schemes 2 and 3. In addition, a methyl moiety at the 8 
position of the PTP scaffold was found to confer selectivity 
for the A3 AR subtype. For these reasons, Pastorin et al. [32] 
decided to apply a well-known procedure for the 
regioselective preparation of the N1-methyl-3-amino-4-
cyano-pyrazole (41). [33,34] Compound 41 was then used as 
starting material for the synthesis of the desired 8-methyl-
PTP (42) which allows to easily explore the SAR of these 
derivatives. [33] The synthesis involved the formation of a 
hydrazone (39) between methylhydrazine (38) and 
benzaldehyde. This initial synthetic step allowed the 
protection of the non-alkylated nitrogen of methylhydrazine, 
thus directing the subsequent reaction with ethoxymethylene 
malondinitrile on the methylated nitrogen (compound 40). 
Scheme 5. Reagents: i: PhCHO, EtOH, rfx, 3h; ii: (CN)2CCHOC2H5, C6H6, rfx, 1h; iii: HCl conc., EtOH, rfx, 0.5h; iv: see 
scheme 1. 
 
Scheme 4. Reagents: i: NH2NH2.H2O, DIPEA, DMF, rt, 4h; ii: RX, NaH, DMF, 0°C-rt, overnight (for compound 35 
RX=ClCH2CH2Br); iii: NH2NH2.H2O or ArCONHNH2, DIPEA, CH3CN, rt, overnight; iv: R1COCl, DIPEA, DMF, rt, 2h or 
R1COOH, HOBt, EDCI, DMF, rt, 1h; v: BSA, HMDS, 120°C, overnight; vi: BocNHNH2, DMF, 80°C, 18h; vii: 1-aryl-
piperazine, KI, DMF, 90°C, 68h; viii: 4M HCl in dioxane, MeOH-DCM (1:1), rt, 16h. R = arylalkyl, arylthioalkyl, 
aryloxyalkyl, (4-susbstituted-piperazin-1-yl)alkyl  R1 = Ar, phenyl, pyrrol-2-yl and their substituted derivatives, or nicotinoyl or 
cyclopent-1-en-1-yl, Ar = fur-2-yl, thien-2-yl. 
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The desired N1-methylpyrazole (41) was obtained by 
cyclization of compound 40 in a concentrated solution of 
hydrochloric acid and then converted to the 2-(furan-2-yl)-8-
methyl-8H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-
amine (42) following Gatta et al.procedure. [26,32] (Scheme 
5) 
 A detailed SAR analysis of the PTP nucleus at the ARs 
was obtained through investigations on the 5 position of the 
8-substituted-PTP scaffold. [30,32,35-41] In particular, the 
treatment of the 5-amino derivatives (43) with various 
acylchlorides or isocyanates afforded the corresponding 5-
amido (44) or 5-ureido (45) PTP compounds (Scheme 6). In 
the same conditions, the coupling reaction with isocyanates 
failed in the case of the 7-substituted-PTP pattern of 
substitution, probably due to the less nucleophilic character 
of the amino group at the 5 position. In fact, the nitrogen 
lone pair of the 5-amino group in 7-substituted derivatives is 
more extensively delocalized on the heterocyclic ring, than 
in the 8-substituted derivatives. [35]  
 An alternative functionalization of the 5 position of PTP 
was obtained by conversion of the 6,7-dihydro-5H-
pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one (47) to 
the  5-chloro-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine 
derivative (48), which could be easily reacted with different 
moieties containing an amino group. Federico et al. [42] 
reported a method to obtain compound 47 alternate to that of 
Gatta et al. and previously described by Francis et al. [44] 
for the triazoloquinazoline nucleus (Scheme 7). Following 
this method, the tricyclic urea 47 was prepared by reaction of 
the corresponding triazolylpyrazole (46) with diphosgene in 
dioxane at reflux. Then, the 5-chloro derivative was obtained 
by treatment of compound 47 with phosphorous oxychloride, 
phosphorous pentachloride and pyridine. The simple reaction 
of the 5-chloro derivative with three equivalents of the 
desired amino compound, in hot ethanol, gave a large series 
of 5-aminosubstituted-PTP derivatives (49).  [42-43]  
 Finally, Okamura et al. reported a one-pot synthesis of 
fused 1,2,4-triazolo[1,5-c]pyrimidines, including 
pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives 
(51), which were obtained with very good yields, ranging 
from 62% to 82% (Scheme 8). PTP derivatives (51) were 
synthesized by condensation of desired iminoesters 50 and 
arylhydrazide. The iminoester 50 was previously obtained, in 
the same vessel, by reacting the cyanoaminopyrazole (16) 
with a substituted orthoester (e.g. trimethyl orthovalerate) in 
the presence of 1% of CSA (dl-camphorsulfonic acid) in 
DMF. [45,46] 
 
2.2. Structure activity relationship 
Scheme 6. Reagents: i: RCOCl, TEA, THF, rfx, 18h; ii: RNCO, rfx, 12-18h. Ar = 2-furyl, Ph or substituted-Ph. R = alkyl or 
arylalkyl, R1 =alkyl, aryl, arylalkyl, R2 = aryl. 
 
Scheme 7. Reagents: i: ClCOOCCl3, dry dioxane, 70°C, 1.5h; ii: POCl3, PCl5, Pyr, rfx, 24h; iii: R1RNH2, EtOH, 110°C, sealed 
tube, 2h. R = alkyl, cycloalkyl, aralkyl, aminoalkyl, hydroxylalkyl; R1 = H, alkyl, cycloalkyl, aralkyl, hydroxylalkyl. 
 
Scheme 8. Reagents: i: n-BuC(OCH3)3, 1% CSA, DMF, rt, 1-6h; ii: ArCONHNH2 was added in the same vessel, rfx, 1-6h. Ar 
= Ph or substituted Ph. 
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A2A AR antagonists 
 Gatta and coworkers developed the first series of PTP as 
AR antagonists. [26] As depicted in Scheme 1, in this 
preliminary work five different PTP scaffolds have been 
synthesized: 7-substituted-3,7-dihydro-2H-pyrazolo[4,3-
e][1,2,4]triazolo[1,5-c]pyrimidin-2-one (10), 2,7-
disubstituted-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-
c]pyrimidine (12), 5-amino-2,7-disubstituted-7H-
pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine (15)  and 5-
amino-2,8-disubstituted-8H-pyrazolo[4,3-
e][1,2,4]triazolo[1,5-c]pyrimidine (19). The most promising 
compounds at the A2A AR were found among the 5-amino-
pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines (15,19). In 
particular, 8-FB-PTP (52) showed the highest affinity at the 
A2A AR (Ki = 1.2 nM), whereas 7-FB-PTP (53) displayed a 
decreased affinity at the A2A AR (Ki = 12 nM) but a better 
selectivity against the A1 AR than compound 52 (53, A1/A2A 
= 15.8 vs 52, A1/A2A = 2.8). [26,29] These compounds 
(52,53) bear a free amino group at the 5 position, a 4-
fluorobenzyl moiety at the 7 or 8 positions and a 2-furyl ring 
at the 2 position (Figure 4). Further investigations were 
performed on the pyrazole substitution, maintaining the 
optimal NH2 and 2-furyl groups at the 5 and 2 positions, 
respectively. PTP was substituted on the pyrazole ring, at the 
7 and 8 positions, with alkyl or aralkyl moieties, confirming 
that the 7 substitution improved selectivity at the A2A AR, as 
clearly demonstrated by comparing compound 54 (Figure 4) 
with its corresponding 8-β-phenylethyl derivative, which 
were 52.6 and 3.4 fold selective for the rA2A vs rA1 ARs 
compound, respectively. In addition, among 7 substitutions, 
arylalkyl moieties (e.g. 7-(3-phenyl)propyl, compound 55, 
SCH63390) were found to confer higher selectivity at the 
A2A AR than alkyl moieties (e.g. 7-n-butyl, compound 56). 
[29,47] Compound 54, named SCH58261, was synthesized 
also in its triatiated form, [
3
H]SCH58261, which 
demonstrated to label A2A receptors with high affinity (KD = 
0.7 nM) and high specific binding (> 90%). [48] 
Furthermore, SCH58261 (54) maintained antagonism at the 
A2A AR in in vivo cardiovascular models and behave as a 
central nervous system stimulant, like caffeine. [29]  
 Nevertheless, compounds 52-56 are highly lipophilic 
compounds presenting poor solubility in water. In order to 
enhance the hydrophilic character of PTP derivatives, while 
retaining high affinity and selectivity at the hA2A AR, several 
polar moieties have been introduced on the aryl group of the 
substituent at the 7 position. [49,50] All the synthesized 
compounds showed a good affinity and selectivity for hA2A 
AR with different degrees of selectivity over the hA1 AR. On 
the other hand, all compounds were inactive at the hA2B and 
hA3 ARs. As previously demonstrated, the best length for the 
side chain is three methylene groups between 7 and the aryl 
moiety. In fact, promising results were obtained introducing 
a hydroxyl group at the para position of the phenyl ring of 
SCH63390 (55), which increased both affinity and 
selectivity at the rA2A AR (compound 57). Also the para-
methoxy derivative, SCH442316 58, demonstrated to be a 
potent and selective A2A AR antagonist, both at the human 
and rat receptors (rA2AAR Ki = 5.3 nM, rA1/rA2A = 487; 
hA2AAR Ki = 2.7 nM, hA1/hA2A = 611). [49] Starting from 
compound 57, SCH442316 (58) can be obtained in its 
11
C 
form ([
11
C]SCH442316), and used as radioligand in positron 
emission tomography (PET). [51] Amino (compound 59) 
and aminomethylene substitutions improved selectivity 
versus the A1 AR the polar groups were not sufficient to 
confer water solubility to the derivatives. On the contrary, 
the carboxylic acid moiety and, in particular the sulfonic acid 
group improved water solubility of compounds but affinity at 
the A2A AR was decreased (e.g. compound 60). [50] 
 Interestingly, SCH63390 (55) was conjugated with a 
fluorescent moiety, Alexa-Fluor 488, by a N-(2-
aminoethyl)amido linker, affording MRS5346 (61) which 
was used in A2A adenosine receptor fluorescent polarization 
assays in place of traditional radioligand based binding 
studies. MRS5346 (61) possessed a Ki affinity value of 111 
nM at the hA2A AR, but it was inactive at the other AR 
subtypes at 10 μM concentration. [52,53]  
 Because the goal to achieve water solubility by 
introducing polar group on the phenyl ring of 7-arylalkyl-
PTP failed, an additional piperazine ring was introduced as a 
spacer between the aryl and the alkyl moieties at the 7 
position. The aryl ring consists in a phenyl ring variously 
substituted, in particular at the para position. All the 
developed compounds displayed affinities in the low 
nanomolar range and retained selectivity over A1 AR (Figure 
5). [5] Considering that compounds were developed as 
promising therapeutic agents in PD, they were orally 
employed in the rat haloperidol-induced catalepsy model. 
The first compound to be tested was the unsubstituted phenyl 
derivative (62), which exhibited a good oral activity at 1h 
post-dose, but became inactive after 4 h. Inactivation is due 
to metabolic conversion to the para-hydroxyl derivative (63) 
which, despite its high affinity at the A2A AR (hA2AAR Ki = 
1.3 nM), shows inactivity at an oral dose of 1 mg/Kg. For 
these reasons, several derivatives bearing substituted phenyl 
moieties, able to extend the duration of action, were 
developed. Among them, 2,4-difluorophenyl derivative 
(SCH412348, 64) displayed potent oral activity, but its 
solubility remained poor. The strategy to improve water 
solubility of those compounds was to introduce ether-linked 
substituents. Also in this case, all the derivatives showed 
nanomolar or subnanomolar affinities at the hA2A AR. The 
most interesting compound was the 4-methoxyethoxy 
derivative (2), named SCH420814, which exhibited a robust 
oral anti-cataleptic activity and a solubility in water, as the 
crystalline free base, of 0.2 µM at native pH (5.1), and 2 mM 
in 0.01 N HCl. [5] SCH420814 (2) was subjected to 
extensive profiling, reaching also clinical trials under the 
name of Preladenant (see Section 2.3). [6-8] 
 
A3 AR antagonists 
 The rationale for the development of PTP derivatives as 
A3 AR antagonists consists in hybridization between the PTP 
core, known to behave as antagonist at the A2A ARs, and the 
arylcarbamoyl moiety of potent rA3 AR agonists (such as 
compound 65 in Figure 6), which were known to confer 
affinity for the rA3 AR subtype. [54,35] Since the coupling 
reaction with isocyanates was successful using 8 alkylated 
compounds, but it failed in the case of the 7 pattern of 
substitution (see Section 2.1 Chemistry), only 8-substituted 
derivatives were developed.  
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All the synthesized compounds showed high affinity at the 
hA3 AR (e.g. nanomolar or subnanomolar affinities), with 
different degrees of selectivity depending on both arylureido 
and (ar)alkyl substitutions present at the 5 and 8 positions, 
respectively. Also compounds lacking the phenylcarbamoyl 
moiety at the N5 position were assayed at the various AR 
Figure 4. PTP derivatives as A2A AR antagonists: compounds 52-61. 
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subtypes, showing high affinity for the A2A AR, with low 
selectivity versus the A1 AR (as observed for 8-FB-PTP (52) 
compound) and low affinity  at hA3 AR subtypes. [30,35] A 
clear example of this behavior is obtained by comparing 
compound 66 with compound 67 in Figure 6. Compound 66, 
bearing a free amino group at the 5 position, was a poorly 
selective A2A AR antagonist (hA2AAR Ki = 0.34 nM; A1/A2A 
=2.9), whereas, the introduction of the para-
methoxyarylcarbamoyl moiety on the amino group at the 
same position led to a potent and quite selective A3 AR 
antagonist (67, hA3AR Ki = 0.98 nM; A1/A3 = 205; A2A/A3 = 
122). [30,35] An in-depth investigation on the 8 position, by 
introducing various alkyl and arylalkyl moieties, revealed 
that small alkyl groups, such as methyl, were the optimal 
substituents, conferring high affinity at the A3 AR subtype 
and good selectivity over the other AR subtypes (i.e. 
compound 68, hA3AR Ki = 0.20 nM; A1/A3 = 5,485; A2A/A3 
= 6,950). [30]  Starting from the 8-allyl compound 69, [30] it 
was possible to obtain the corresponding tritiated derivative, 
which bears a 8-propyl group, named [
3
H]-MRE-3008-F20 
(70), the first selective radioligand  for the hA3 AR behaving 
as antagonist. [55,56]  
 Later, also the N5 position was deeply investigated. First 
of all, different substituents (e.g. chloro, fluoro, bromo, 
methyl, methoxy, nitro, sulfonic acid, trifluoromethyl) have 
been introduced at the ortho, meta and para positions of the 
phenyl ring of the 5-phenylureido group, while maintaining a 
small alkyl group at the 8 position. Curiously, all the 
compounds affinity values at A3 AR were in the range 0.16-
3.7 nM, except for derivatives bearing a para-sulfonic acid 
group which dispayed a Ki value above 25 nM (i.e. 
compound 71), indicating that para-substituent is surrounded 
by a lipophilic environment inside the A3 AR binding cleft. 
Molecular modeling studies on the hA3 AR suggested that a 
steric control is present at the para and, especially, at the 
meta positions of the phenyl ring. [36] One of the most 
potent and selective compounds of this series was the 
unsubstituted compound 72, which showed a Ki of 0.16 nM 
at A3 AR and > 2000-fold selectivity for A3 over A1 and A2A 
ARs. The replacement of phenylureido moiety with a 
phenylacetyl moiety, maintained affinity at the hA3 AR, 
while a slight decreased selectivity was observed (compound 
72 vs compound 73 in Figure 6). [36] Instead, the 
introduction of a shorter amide, such as the benzamide 
(compound 74) had a detrimental effect on affinity at the A3 
AR (i.e. compound 74, hA3AR Ki = 15.7 nM). [57] In order 
to achieve water solubility of these lipophilic compounds, 
and taking in account the steric control which is present 
around para position, the phenyl ring at the 5 position was 
replaced with a pyridine ring. In addition, the position and 
the basicity of pyridine nitrogen were evaluated. [32,37] The 
most potent compound of the series, which was also the most 
potent A3 AR antagonist ever reported (compound 75), bears 
the 4-pyridinium moiety as hydrochloride salt. (Figure 7) 
Moreover, as all the PTP derivatives, also compound 75 
proved to be inactive in rats. 1 μM concentration of 
compound 75 displaced only 35% of the binding of a 
specific radioligand at rA3 receptors. [32,37] The 4-
pyridylcarbamoyl moiety conferred good water solubility at 
low pH (<4.0) but poor solubility at physiologic pH. Thus, 
the replacement of pyridin-4-yl moiety with a 1-
(substituted)piperidin-4-yl ring was performed to exploit the 
higher basicity of this nucleus and the possibility to generate 
stable, water-soluble salts. The hydrochloride salt of the 1-
(cyclohexylmethyl)piperidin-4-yl derivative (76, hA3AR Ki 
= 9.7 nM; A1/A3 = 351; A2A/A3 > 515) showed a solubility of 
8 mg/mL at physiological pH and gave a stable aqueous 
system suitable for intravenous infusion. [41]  
More recently, an extensive exploration of a large variety of 
polyfunctionalized chains (i.e. alkylamino, arylalkylamino, 
heterocyclic moieties) at the 5-position has been reported. 
Almost all the synthesized compounds showed affinity for 
the hA3 AR in the nanomolar or subnanomolar range, with 
different levels of selectivity over the other AR subtypes. 
Figure 5. PTP derivatives as A2A AR antagonists: compounds 62-64. 
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The most potent and selective antagonist of the series bears 
an (S) α-phenylethylamino moiety at the 5 position (77, 
hA3AR Ki = 0.3 nM, A1/A3 = 1,127; A2A/A3 = 184). Good 
results in terms of affinity were obtained also with small 
branched alkylamines and with several benzylamines, 
however their selectivity versus the other ARs was poor (e.g. 
Figure 6. PTP derivatives as A3 AR antagonists: compounds 65-74. 
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compound 78, A1/A3 = 25; A2A/A3 = 47.4). [42]  
 Substitution at position 2 of the PTP tricyclic system has 
not been deeply explored, being essentially limited to the 
introduction of a furyl group. Baraldi et al. have found that 
the substitution of the furan ring with phenyl or substituted- 
phenyl and furyl rings led to a loss of affinity at all the AR 
subtypes. Remarkably, substitution at the pyrazole ring of 
PTP nucleus occurred at the 7 rather than at the 8 position. 
[58] In addition, several reported tricyclic hA3 AR 
antagonists bear a substituted phenyl moiety at the position 
equivalent to that of furan ring in PTP derivatives. [59] For 
these reasons, Cheong and coll. [39] designed and 
synthesized a series of PTP bearing a (para-substituted)-
phenyl ring at the 2 position, while maintaining either methyl 
or phenyl-ethyl groups at 8 position and a free amine, 
phenylacetamide or (bis-)benzamide at the 5 position. 
Interestingly, 5-amino derivatives were unselective AR 
antagonists (i.e. compound 79), whereas the 5-
phenylacetamido derivatives retained high affinity at the hA3 
AR and showed a remarkably improved selectivity profile 
toward the other AR subtypes in comparison to the 2-furyl 
PTP derivatives (e.g. compound 80, hA3AR Ki = 0.241 nM; 
A1/A3 > 124,000; A2A/A3 > 415,000 vs compound 73, 
hA3AR Ki = 0.81 nM; A1/A3 = 877; A2A/A3 = 522). [39] 
 Okamura et al. developed different fused 1,2,4-
triazolo[1,5-c]pyrimidine derivatives as A3 AR antagonists, 
including 5-n-butyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-
c]pyrimidines. (Figure 7) Concerning the 2 position of the 
PTP scaffold, different substituted phenyl moieties have 
been introduced, confirming that the selectivity at the hA3 
AR over the hA2A AR was greater with 4-substituted-phenyl 
moieties than with 2- or 3- substituted-phenyl groups, or 
Figure 7. PTP derivatives as A3 AR antagonists: compounds 75-83. 
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with no substitution (e.g. compound 81 (4-F-Ph), hA3AR Ki 
= 1.9 nM; A1/A3 = 321; A2A/A3 > 5,263 vs compound 82 
(Ph), hA3AR Ki = 2.1 nM; A1/A3 = 12.9; A2A/A3 = 90.5). 
[46]  
 Finally, also the 9 position was examined by Baraldi et 
al. by introducing substituents with different steric and 
hydrophilic/lipophilic features, such as: alkylamino, 
arylamino, alkylthio or N-methylpiperazino moieties. These 
compounds maintained the classical methyl group at the 8 
position and the free amino, phenylureido or arylacetamido 
moieties at the 5 position of the PTP nucleus. [57] Notably, 
the introduction of a substituent at the 9 position led to a 
complete loss of selectivity, even if affinity at the ARs in the 
nanomolar range was maintained. Generally, the methylthio 
group at the 9 position was the best tolerated, such as in 
compound 83, which exhibited Ki values lower than 35 nM 
at the four AR subtypes. [58] 
Antagonists for other AR subtypes 
 Although a clear SAR profile for the PTP derivatives 
have been outlined at the A2A and A3 ARs, a similar 
correlation at the A1 and A2B ARs is still lacking (Figure 8). 
Concerning both A1 and A2B AR subtypes, potency was 
achieved but selectivity was very poor. Nevertheless, some 
common features could be observed in the potent, even if not 
selective, PTP A2B antagonists. In fact, substitution at the 8 
position was preferred to that at the 7 position for binding at 
the A2B AR; moreover, arylalkyl or branched alkyl moieties 
were preferred to small alkyl moieties. Compounds 66 
(Figure 6) and 84 (Figure 9), bearing a phenylethyl and 
isopentyl groups at the 8 position, respectively, showed 
affinity in the nanomolar range at the A2B AR (e.g. 66, 
hA2BAR Ki = 5.1 nM; 84, hA2BAR Ki = 9.1 nM). [30] A 
slight improvement of selectivity towards A2A AR was 
achieved by introducing a γ-aminobutyrylamido or a 
phenylacetamido group at the 5 position of the PTP nucleus 
(compounds 85 and 86), but unfortunately a simultaneous 
loss of selectivity over the A1 and A3 ARs was observed. 
[30,60] 
 Even regarding the A1 AR subtype, 8-substituted-PTPs 
showed improved affinity if compared to the 7-substituted 
derivatives: see compounds 53 and 54 (Figure 4) versus 
compounds 52 and 66 (Figures 4,6), which bear an arylalkyl 
group at the 7 and 8 position, respectively. [30] In addition, 
substitution on the amino group at the 5 position of 8-
substitued PTP derivatives seemed to have a detrimental 
effect in terms of affinity at the A1 AR. In fact, compound 86 
(Figure 9), which is the 5-phenylacetyl derivative of 
compound 66, displayed a 120-fold detrimental effect on 
affinity value at the hA1 AR (86, hA1AR Ki = 120 nM; 66, 
hA1AR Ki = 1 nM). [30,38] 
 
2.3 Preladenant: a case study 
 Preladenant (SCH420814, 2), 2-(furan-2-yl)-7-(2-(4-(4-
(2-methoxyethoxy)phenyl)piperazin-1-yl)ethyl)-7H-
pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, is a 
pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivative 
developed by Schering in a program focused on searching 
A2A AR antagonists for the treatment of PD. PD is a 
neurological disorder characterized by  bradykinesia, rigidity 
and tremor. These symptoms are mainly due to degeneration 
of dopaminergic nigrostriatal neurons and to the resultant 
depletion of striatal dopamine. [61] In the central nervous 
system (CNS), the A2A ARs are almost exclusively expressed 
in dendritic spines of the striatopallidal neurons and 
colocalize with the D2 receptors. Further studies 
demonstrated that A2A ARs functionally oppose the actions 
Figure 9. PTP derivatives as unselective AR antagonists. 
 
Figure 8. Structure activity relationship of PTP derivatives 
at ARs. 
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of dopamine D2 receptors on GABAergic striatopallidal 
neurons. In fact, A2A ARs and D2 receptors have also been 
found to form heteromers. These findings raised the 
possibility to use A2A AR antagonists to reduce the 
postsynaptic effects of dopamine depletion, and in turn 
diminish the motor deficits of PD. [61,62] 
 Schering-Plough Research Institute, starting from the 
observation that SCH58261 (54) is a promising A2A AR 
antagonist with a PTP scaffold, has developed a new series 
of derivatives with the aim to simultaneously enhance 
selectivity among the other ARs and improve 
pharmacokinetic properties of the PTP compounds. A variety 
of 7-alkylated PTPs were prepared, in particular, 7-(4-
arylpiperazin-1-yl)ethyl derivatives were of particular 
interest. Almost all the synthesized derivatives showed high 
A2A AR binding affinity, with high selectivity over A1 AR. 
Further efforts were directed toward improving solubility by 
introducing ether-linked substituents at the para position of 
the aryl moiety; these compounds maintained high affinity 
and selectivity at the hA2A AR. The most promising 
compound resulted to be SCH420814 (2), then named 
Preladenant (2). [5] Preladenant (2), whose synthesis is 
reported in Scheme 9, it is prepared by alkylation of 
compound 21 (obtained as shown in Scheme 3) with 
ethylene glycol ditosylate, which afforded the desired 
tosylate derivative 87 as the major product, along with minor 
amounts of the 8-alkylated compound. Amination of 
compound 87 with the N-arylpiperazine 88 in DMF at 80 °C 
afforded Preladenant (2) in good yields. The necessary N
1
-
(4-(2-methoxyethoxy)phenyl)piperazine (88) is obtained by 
reacting the 1-acetyl-4-(4-hydroxyphenyl)piperazine (90) 
with sodium hydride in DMF and then adding the 2-bromo-
ethylmethylether. [31] 
 In a preliminary profiling, Preladenant (2) exhibited high 
affinity for both human and rat A2A ARs, with Ki values of 
1.1 and 2.5 nM, respectively. In addition, the compound was 
more than 1000-fold selective for hA2A ARs over hA1, hA2B 
and hA3 ARs. In cell-based assays, Preladenant (2) blocked 
adenylate cyclase activity stimulated by the A2A AR agonist 
CGS21680 with Kb values of 0.7 nM (rat) and 1.3 nM 
(human), confirming that it is an antagonist. The compound 
did not show significant binding at a concentration of 10 μM 
against a panel of 60 other receptors, ion channels and 
transporters. In vivo, SCH420814 dose-dependently reversed 
haloperidol-induced catalepsy (haloperidol is a D2 receptor 
antagonist) in the rat and in the squirrel monkeys. The 
solubility of Preladenant (2) as crystalline free base in water 
is 0.2 μM at native pH (5.1) and 2 mM in 0.01 N HCl. [5] 
One of the drawbacks of current dopamine replacement 
therapies for PD is the development of dyskinesias after 
chronic activation of D2 receptors, which correlates with an 
increased number of A2A ARs. Therefore, treatment with an 
A2A AR antagonist, by blocking the upregulated A2A AR and 
avoiding the direct activation of D2 receptors, may 
ameliorate PD symptoms while reducing the risk of 
developing dyskinesias. In rodent models of PD, Preladenant 
(2) demonstrated to be efficacious without leading 
dyskinesias both as monotherapy or coupled with L-Dopa. In 
addition, PD patients often suffer depression and Preladenant 
(2) gave positive results in the FST (forced swim test) and 
TST (tail suspension test) models of behavioral despair, 
suggesting the potential use of A2A AR antagonists in the 
treatment of also non-motor PD symptoms. Supported by all 
these results, Preladenant (2) has become an excellent 
candidate for clinical studies on the treatment of both the 
motor and non-motor symptoms of PD. [6] 
 In a phase I study, the safety, tolerability and 
pharmacokinetics of Preladenant (2) at single and multiple 
oral doses were evaluated. Preladenant (2) was generally 
tolerated up to 200 mg/day after oral administration of both 
single dose and multiple doses for 10 consecutive days. 
Preladenant (2) reached peak plasma concentrations in about 
1 h and then declined rapidly; the effective half-life was 
about 8 h. [63] A phase II study displayed that 5 and 10 mg 
Preladenant (2) twice daily might be clinically useful to 
reduce off time in Parkinsonian patients with motor 
fluctuations who are receiving levodopa and other 
antiparkinsonian drugs (1 and 2 mg of Preladenant (2) are 
Scheme 9. Reagents: i: ethylene glycol ditosylate, NaH, DMF, N2, rt, 24h; ii: compound 88  DMF, 80°C, 20h; iii: NaH, DMF, 
CH3OCH2CH2Br, rt, 18h, followed by HCl 6N, rfx, 1h. 
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ineffective). Mild transient increases in blood pressure were 
observed and these are consistent with the expected 
biological effects of A2A AR inhibition. [64] These results 
were confirmed by a second phase II study, which evaluated 
the long-term safety and efficacy of Preladenant (2). [65] 
Preladenant (2) was prepared also in its radiolabeled form 
14
C-preladenant (Preladenant (2) was labeled at the carbon at 
position 2) and orally administered in human healthy 
subjects in order to study its metabolism and excretion. The 
identified metabolites of Preladenant have been depicted in 
Figure 10 and principally consist of O-demethylation and 
subsequent oxidation, N-dealkylation and furan ring 
opening. After a single administration of Preladenant (2), the 
dose was principally eliminated in feces (>65%) while a 
minor part of the dose was eliminated in urine (<10%). In 
plasma were identified both Preladenant (2) and its 
metabolites 92 and 93. In the feces, the 14% of the dose is 
the unaltered drug, while the major metabolites are 
compounds 92 (29%), 91 (22%) and 90 (6%). In urine 
Preladenant (2) was not detected and the most prevalent 
metabolite is compound 92 (3.53%). Among the identified 
metabolites, compounds 92-94 retain high affinity at the 
hA2A AR. [66] 
 Unfortunately, phase III clinical trials of both adjunctive 
and monotherapy with Preladenant (2) in patients with PD, 
failed to prove drug efficacy. Nevertheless, trials were also 
unable to identify benefit for rasagiline, the active control; 
therefore it is difficult to interpret these results and what they 
mean for Preladenant (2) in early Parkinson's disease. [7,8]  
3. [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINES 
Figure 10. Preladenant metabolites. 
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 The [1,2,4]triazolo[1,5-c]pyrimidine (TP) is a versatile 
scaffold, which has been reported to bind different protein 
targets depending on the pattern of substitutions present on 
its structure, [67,70] including adenosine receptors [9-14]. In 
fact, TP nucleus (3) is a clearly structural simplification of 
the PTP scaffold (1), in which pyrazole ring has been 
removed. (Figure 11) Here are reviewed chemistry and SAR 
profile relative to TP derivatives developed as AR 
antagonists. 
3.1. Chemistry 
 Kyowa Hakko Kogyo Co. was the first company to 
develop TP derivatives for their use as A2A AR antagonists. 
[9] The Japanese company deeply explored the chemistry of 
TP compounds as evidently shown in Schemes 10-12. 
Several alternative approaches could be used to prepare the 
TP compounds; in particular, modifications in the series of 
the reaction steps allow to introduce the desired substituents 
on the TP nucleus. The starting material could be a 
compound of general structure 96 (Scheme 10). 4,6-
dichloro-2-(methylthio)pyrimidine but also some 4,6-
dichloro-5-substituted-2-(methylthio)pyrimidines are 
commercially available or easily achievable by synthesis. 
Figure 11. TPs as simplified analogs of the PTPs. 
 
Scheme 10. Reagents: i: R2H, NaH, THF, 0°C-rt, 4h; ii: R3CONHNH2, DBU, DMF (or dioxane-water 3:1), 100°C, 5h; iii: 
P2O5, HMDSO, xylene, 90°C, 2h, rfx, 5h; iv: veratrylamine or R2H, DMSO, 140°C, 2-4h; v: TFA, anisole, CF3SO3H, 0°C-rt, 
4h; vi: R3CONHNH2, DBU, THF, rt, 5h; vii: R2H, DMAP, rfx, overnight or R2H, DMSO, 130°C, overnight; viii: R2H, DBU, 
THF, rfx, 3h; ix: purification by column chromatography; x: THF, DBU, 0°c-rt, 1h, veratrylamine, 50°C, 3h; R1 = H, CH3 or 
Ph; R2 = aryloxy, arylthio, benzylthio, piperidino, morpholino, piperazino, N1-substituted-piperazino and various other 
saturated nitrogen containing heterocycles; R3 = furyl, thienyl, Ph, 3-pyr, 3-OCH3Ph. 
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 One synthetic approach considered the consecutive 
substitution of the two chlorine atoms on the pyrimidine ring 
(96): the first with nucleophilic compounds such as amines, 
alcohols and thiols, obtaining compound 97, and then the 
second with the appropriated aryl hydrazide, which afforded 
compound 98. These two steps could be inverted (103, 98) 
and, in both cases, the first substitution was made at room 
temperature in the presence of a base, whereas the second 
required heating. The hydrazido derivative 98 underwent 
dehydrative cyclization with phosphorous pentoxide and 
hexamethyldisiloxane (HMDSO), which formed the 
dehydrating agent polyphosphoric acid trimethylsilyl ester 
(PPSE), in xylene. TP derivative 99 was obtained by 
Dimroth rearrangement of [1,2,4]triazolo[4,3-c]pyrimidine 
derivative 100, which generally occurred during the reaction. 
In some cases, only compound 99 were isolated, indicating 
that rearrangement was favored. Compound 99 were reacted 
with veratrylamine in DMSO (dimethylsulfoxide) at 140°C 
to afford compound 101, which is a 5-amino-TP derivative 
protected on the amino group with veratryl moiety. Also this 
reaction facilitates Dimroth rearrangement, so reaction could 
also be made on the unpurified mix of compounds 99 and 
100. Deprotection of amino group at the 5 position of 
compound 101 was obtained by treatment with 
trifluoroacetic acid (TFA), triflic acid and anisole. This last 
step led to the desired 5-amino-7,8-disubstituted-TPs (102).  
Alternatively, a chlorine atom of the starting pyrimidine 
derivative (96) could be maintained during all the synthesis, 
following the same reactions depicted above with slight 
modifications.  
Scheme 11. Reagents: i: RB(OH)2, (PPh3)2PdCl2, Na2CO3, THF, rfx, 9h, or (n-But)3SnR, (PPh3)2PdCl2, toluene, rfx 9h, with R 
= Ar, arylalkyl, alkylethynyl, arylethynyl, vinyl; ii: a) tert-butyl-dimethyl-(tributylstannylmethoxy)silane, (PPh3)2PdCl2, 
toluene, rfx, 8h, b) TBAF, THF, rt, 1h; iii: ArOH, PPh3 and DEAD, rt, 1-12h or ArOH, 
(Tributylphosphoranylidene)acetonitrile, THF, 120°C, 19-25h; iv: a) TFA, anisole, CF3SO3H, rt, 7h, b) MnO2, DMF, rt, 20h; v: 
a) AcOH, NH2SO3H, b) NaOCl, rt, 4h; vi: RR1NH, Na(CH3COO)3BH, rt, 16h; vii: bis(tributyltin), (PPh3)2PdCl2, DMF, 100°C, 
9h; viii: RCOCl, (PPh3)2PdCl2, THF, rfx, 10h, with R = Ar. 
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This approach allows access to larger quantities of precursor 
(107) which could be then substituted with the desired 
substituents at the 7 position. Furthermore, the chlorine atom 
may be substituted after cyclization step, leading to 
Scheme 12. Reagents: i: fur-2-yl-CONHNH2, DBU, THF, rt, 5h; ii: P2O5, HMDSO, xylene, 90°C, 2h, rfx, 5h; iii: 
veratrylamine, DMSO, 140°C, 2-4h; iv: CH3ONHCH3, R1MgBr, THF, -10 -60°C, 13h; v: TFA, CF3SO3H, rt, 19h, 50°C, 1.5h; 
vi: LiOH.H2O, EtOH, H2O, rfx, 3h; vii: CH3ONHCH3, EDCI, HOBt, DMF, rt, 70h, 50°C, 1.5h; viii: R2R1NH, SO2Cl2, pyr, rt, 
1h; ix: R2R3NH, i-PrMgCl, THF, -5-4°C, 8h; x: R1MgBr, THF, rt, 1.5-4h; xi: TFA, anisole, CF3SO3H, 0°C-rt, 4h; xii: DIBAL, 
DCM, -78°C, 1h, 0°C, 2h; xiii: MnO2, DCM, rt, 2h; xiv: R4R5NH, ClCH2CH2Cl, AcOH, Na(CH3COO)3BH, 0°C-rt, overnight; 
xv: PCC, silica gel,  DCM, rt, 4h. 
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compound 108, which by reaction with veratrylamine gave 
compound 101. In conclusion, such synthesis is a very 
versatile approach, allowing to perform the substitution at 
the 7 position in any step of the reaction. [9,71] 
 Scheme 11 shows the most important substitutions, 
involving the 7 position, obtained using the 7-chloro-N-(3,4-
dimethoxybenzyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-
c]pyrimidin-5-amine (109) as starting material. Derivatives 
of general formula 110 have been synthesized by carbon-
carbon coupling reactions. This allows the insertion of aryl, 
arylalkyl, arylethynyl or vinyl moieties at the 7 position, 
which in turn may be functionalized in order to obtain more 
complex derivatives.  
The Stille reaction between compound 109 and tert-butyl-
dimethyl-(tributylstannylmethoxy)silane, followed by 
deprotection of hydroxy group, afforded the 7-
hydroxymethyl-TP (111). The 7-aldehyde derivative (113) 
was obtained by deprotection of the amino group at the 5 
position and oxidation of the hydroxy moiety at the 7 
position of compound 111. Further oxidation of compound 
113 afforded the corresponding carboxylic acid (114), which 
may be treated with coupling reagents for the synthesis of 
amides.  On the other hand, reductive amination of 
compound 113 with the desired amine and sodium 
triacetoxyborohydride led to 7-(substitutedamino)methyl-TP 
derivatives (115). Finally, the hydroxyl group of compound 
111 may be converted by Mitsonobu recation in the 
corresponding arylether derivatives (112). The last example 
of different substitutions that can be applied at the 7 position 
of the 7-chloro-TP derivative (109) involved its reaction with 
bis(tributyltin) in order to obtain the corresponding organotin 
derivative (116). Compound 116 is a substrate for Stille 
reaction and, in fact, the treatment with acylchlorides gave 
ketone derivatives of general formula 117. [72] 
 Instead, TP derivatives bearing different substituents at 
the 8 position have been obtained using the ethyl 4-chloro-2-
(methylthio)pyrimidine-5-carboxylate (118) as starting 
material. Compound 118 is commercially available but it is 
easily synthesized by condensation between isothiourea and 
diethyl ethoxymethylene malonate in basic condition, which 
led to a pyrimidine sodium salt that after treatment with 
phosphorous oxychloride afforded compound 118. [73] As 
displayed in Scheme 12, pyrimidine derivative 118 was 
converted in the ethyl 5-((3,4-dimethoxybenzyl)amino)-2-
(furan-2-yl)-[1,2,4]triazolo[1,5-c]pyrimidine-8-carboxylate 
(121) by following the same procedures shown in Scheme 10 
for the introduction of hydrazide, and the subsequent 
dehydrative cyclization and amination at the 5 position.  
Compound 121 may be deprotected on the amino group to 
afford compound 128 or modified at the 8 position and 
subsequently deprotected to afford the final desired 
compounds. Hydrolysis in basic conditions of the ethyl ester 
group of compound 121 led to the carboxylic derivative 124, 
which was converted to the amido derivatives (126) by 
reaction with mono- or di-substituted amines in the presence 
of thionyl chloride in pyridine. Instead, the coupling reaction 
of compound 124 with N,O-dimethylhydroxylamine, carried 
out by the use of EDCI and HOBt as coupling reagents, 
afforded the Weinreb-Nahm amide 125. The treatment of 
compound 125 with a Grignard reagent led to the 
corresponding ketone derivative (122). When R1 in 
compound 122 in Scheme 12 is an ethyl, the Weinreb-Nahm 
ketone synthesis was performed by one-pot reaction directly 
from the ethyl ester derivative (121). Alternatively, 
compound 121 was reduced to 8-hydroxymethyl (129) 
derivative by diisobutylaluminum hydride, which was in turn 
oxidized with manganese dioxide to obtain the 8-formyl 
derivative (130), analogously to that reported in Scheme 11 
for compound 111 (to obtain compound 113). By reductive 
amination of compound 130, aminomethyl derivatives 132 
Scheme 13. Reagents: i: RR1NH, EtOH, sealed tube, 120°C, 2h; ii: NH3 7N/MeOH, EtOH, sealed tube, 120°C, 2h; iii: 
R4NCO, dry THF, rfx, overnight, or R4CH2COCl, dry THF, TEA, rfx, overnight. R,R1,R2,R3 = alkyl, arylakyl or RR1NH are 
saturated heterocycles with at least one nitrogen as heteroatom. R4X = PhCH2, PhNH, c-C6H11-NH. 
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have been obtained, whereas the Grignard reaction led to the 
secondary alcohols of general formula 134. Compounds 134 
were oxidized by pyridinium chlorochromate to afford again 
ketones with general formula 122. [9,71] 
Recently, our group developed 5,8-disubstituted-TPs based 
on the Kyowa Hakko Kogyo Co. procedure displayed in 
Scheme 12 (Scheme 13). Procedure was slightly modified in 
order to introduce different substituents at the 5 position. 
[14] In fact, compound 120, which was obtained as in 
Scheme 12, was reacted with different amines in hot ethanol 
to afford different 5-amino derivatives (135) in good yields. 
By using ammonia, compound 128 has been directly 
obtained. Compound 128 or compounds of general formula 
127 (obtained as depicted in Scheme 12) were treated with 
appropriated isocyanates or acylchlorides in order to achieve 
the corresponding 5-ureido and 5-amido derivatives (136). 
[14] 
 Schering developed a large series of TP compounds, 
mainly applying a chemistry similar to those applied by 
Kyowa Hakko Kogyo Co. As shown in Scheme 14, Schering 
approach uses directly the 2-amino-4,6-dichloro-pyrimidine 
(137) as starting material. As reported by Kyowa Hakko 
Kogyo Co., a first chlorine atom was substituted with 
amines, alcohols, or thiols to give compounds of general 
formula 138. In this step, different reagents were employed 
on the basis of the nucleophile used (i.e. potassium carbonate 
for amines, sodium hydride for alcohols and sodium sulfide 
with aryl or alkylchlorides for thiols). 
Alternatively, compound 137 may be coupled with alkyl or 
arylalkyl moieties by Suzuki coupling affording compounds 
of general formula 144.  Compounds 138, 144 or the 
unsubstituted derivative 137 were reacted with the desired 
arylhydrazide in acidic (138) or basic conditions (137, 144) 
and derivatives 139, 145 and 141 have been obtained. 
Compounds 139, 141 and 145 were then cyclized in 
dehydrating conditions to the 5-amino-TPs (140, 142, 143). 
Schering applied similar cyclization conditions to that used 
to prepare PTP derivatives, which are BSA at 120°C for 18h. 
An alternative synthetic route was used to introduce different 
aryl moieties at the 2 position of the TP nucleus, which 
involved the reaction between compound 138 and tert-
butylcarbazate, in solution containing HCl, to form the N-
Boc-hydrazine derivative 146. After removal of the Boc 
protecting group, the resulting 6-hydrazinyl-pyrimidines 
(147) were coupled with the desired carboxylic acid by using 
EDCI, HOBt and NMM, thus leading again to compounds of 
Scheme 14. Reagents: i: a) for X = N, RR1NH, K2CO3, EtOH, sealed tube, 90°C, 1h, b) for X = O, ROH, NaH, THF, rfx, 24h, 
c) for X = S, Na2S, DMF, RCl, 80°C, 18h; ii: aryl hydrazide, 1N HCl, EtOH, sealed tube, 90°C, 16h; iii: BSA, 120°C, 18h; iv: 
aryl hydrazide, K2CO3, EtOH, sealed tube, 100°C, 18h or aryl hydrazide, BuOH, 90°C, 20h;  v: for X = N, RR1NH, DBU, 
DMF, 140°C, 2h or RR1NH, CsF, DMSO, 110°C; vi: ArYB(OH)2, Pd(PPh3)4, Na2CO3, 3/1/1 toluene/ethanol/water, 100°C, 4h, 
with Y= none or CHCH; vii: t-butylcarbazate, 4M HCl/dioxane, EtOH, sealed tube, 100°C, 18h; viii: DCM/MeOH, 4M 
HCl/dioxane, rt, 18h; ix: ArCOOH, EDCI, HOBt, NMM, DMF, rt, 3h. Ar = fur-2-yl or 3-CNPh. 
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general formula 139. [11,13,74-75] 
Scheme 15. Reagents: i: R2X, base; ii: ClCOOEt, base;  iii: guanidine carbonate, EtOH, rfx, 20h; iv: POCl3, rfx, 2h; v: 2-furoic 
hydrazide, 4M HCl/dioxane, EtOH, sealed tube, 100°C, 18h; vi: BSA, 130°C, 6h. 
 
Scheme 16. Reagents: i: 2-furoic hydrazide, BuOH, 100°C, 20h; ii: BSA, 120°C, 18h; iii: triflic anhydride, TEA, DCM, 0°C, 
N2, 1h; iv: ArSn(Bu)3, Pd(dppf)Cl2, DMF, 80°C, 64h, N2. 
Scheme 17. Reagents: i: RR1NH, CsF, DMSO, 110°C, 18h; ii: 1-R2-4-prop-2-ynyl-piperazine, Pd(PPh3)4, CuI, PPh3, TEA, 
DMF, N2, 110°C, 18h; iii: Pd/C 10%, 1 atm H2, 1/1 THF/MeOH, rt, 0.5h. 
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 Schering has reported an alternative method to synthetize 
7 and 8 aryl or arylalkyl substituted TP derivatives, as shown 
in Scheme 15. The desired 2-amino-4-chloro-5,6-
disubstituted-pyrimidines (152) were obtained from 
condensation between guanidine carbonate and the 
corresponding β-ketoesters 150, followed by treatment with 
phosphorous oxychloride which introduced a chlorine atom 
in place of hydroxy group of compounds 151 at the 4 
position. The desired β-ketoesters 150 can be obtained both 
by alkylation of a β-ketoesters of general formula 148 and by 
reaction of ketone derivatives 149 with ethylchloroformate. 
The pyrimidines 152 were converted to the final desired 
compounds 154 following the same procedures reported in 
Scheme 13 with slight modifications. [13,74-75]  
 Finally, 5-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-
c]pyrimidin-7-ol (157) was obtained from 2-amino-6-
chloropyrimidin-4-ol (155), as shown in Scheme 16. The 
hydroxyl moiety of compound 157 was treated with triflic 
anhydride to give compound 158, which bears the triflate 
group, a pseudohalide moiety useful for the subsequent Stille 
cross-coupling reaction. Thus, this reaction represents 
another way to obtain 5-amino-7-aryl-2-furyl-TP derivatives 
(159). [75] 
 Biogen Idec also investigated the TP scaffold for 
searching A2A AR antagonists. The company applied a 
strategy very similar to those reported above. In fact, as 
shown in Scheme 17, they used the 7-chloro-2-(furan-2-yl)-
[1,2,4]triazolo[1,5-c]pyrimidin-5-amine (160) to introduce 
different moieties at the 7 position. The 7-susbtituted-amino 
derivatives (161) were obtained as reported above but using 
cesium fluoride as base. Instead, compound 160, by 
Sonogashira cross-coupling reaction with 1-substitited-4-
(prop-2-yn-1-yl)piperazine, followed by a catalytic 
hydrogenation, afforded 7-(4-substitited-piperazin-1-
yl)propyl-TP derivatives (163). [76-78] 
3.2. Structure activity relationship 
 TP derivatives were almost exclusively reported in 
patents. In patents, binding data are often incomplete and 
this makes it difficult to assess the SAR profile of these 
compounds. All the patents on TP derivatives target A2A AR. 
Kyowa Hakko Kogyo Co. developed a series of TP mainly 
maintaining the furyl group at the 2 position and the free 
amino group at the 5 position of TP scaffold, because these 
substitutions were known to confer high affinity at the A2A 
AR subtype in the PTP series (see Section 2.2). The 
introduction of both phenoxy (164) and benzylthio (165) 
moieties led to potent A2A AR antagonists (164, hA2A AR 
displ. at 0.1 µM = 89%; 165, hA2A AR displ. at 0.1 µM = 
82%). Unfortunately, selectivity profile among ARs have not 
been reported for these compounds. [71] (Figure 12) 
Neustadt et al. developed a series of TPs bearing aryloxy, 
arylthio and arylamino moieties at the 7 position. They 
confirmed that all these substitutions led to potent A2A AR 
antagonists, but only derivatives bearing an additional small 
alkyl group on the nitrogen at the 7 position displayed good 
selectivity over the hA1 AR (i.e. compound 166). [13] 
Nevertheless, the most investigated substitution on the TP 
scaffold has been the piperazino group. Kyowa Hakko 
Kogyo Co. found that introduction of N-alkyl-, N-
hydroxyalkyl- or N-aryl- piperazines at the 7 position of the 
TP nucleus led to derivatives that displayed poor affinity at 
the A2A AR (e.g. compound 167, hA2A AR displ. at 0.1 µM = 
42%;  compund 168, hA2A AR displ. at 0.1 µM = 36%). [71] 
Instead, N-arylalkyl-piperazines, with alkyl linkers ranging 
from 1 to 3 methylene groups (i.e. compound 169), increased 
affinity at the A2A AR. Compound 169 was demonstrated to 
be effective in a MPTP model of PD. [71] Furthermore, 
piperazine could also be replaced with a piperidine or a 
1,2,3,6-tetrahydropyridine, such as in compound 171, which 
showed high affinity at the A2A AR. [72] As an extension of 
the series of piperazine derivatives of [1,2,4]triazolo[1,5-
c]pyrimidines, Biogen Idec. explored the possibility to 
introduce a flexible alkyl spacer between the TP nucleus and 
the piperazine moiety. Compounds 172, 173 and 174 clearly 
showed that an aminoethyl spacer gave quite potent and 
selective A2A AR antagonists (172), however methylation at 
the amino group improved both affinity and selectivity at the 
A2A AR (compound 173). Finally, substitution of the amino 
group with a methylene group had a detrimental effect on 
affinity at the A2A AR (compound 174). [76] Schering-
Plough Research Institute developed a large series of 
piperazine and piperidine derivatives using a phenyl ring as a 
linker between the TP nucleus and the heterocyclic group. 
Initially, a series of different 7-aryl compounds have been 
synthesized, demonstrating that an aryl group is well 
tolerated at the A2A AR, with affinity values in the 
nanomolar range. Interestingly, compound 175 showed a 
high affinity at the A2A AR with a good selectivity over the 
A1 AR subtype (hA2A AR Ki= 5.5 nM; A1/A2A= 82). This 
result suggested to explore substitutions at the meta position 
of the phenyl ring at the 7 position of the TP, thus leading to 
the synthesis of several derivatives bearing a 4-(phenyl)-
piperidine or a 4-(phenyl)-piperazine at this position. The 
incorporation of the methoxethoxy substituent, as in 
Preladenant (2), seemed particularly beneficial in terms of 
selectivity over A1. In fact, compound 176, which displayed 
Ki values of 2.8 and 1,680 nM at the A2A an A1 ARs, 
respectively, showed good oral activity at 3 mg/kg in a rat 
catalepsy model. [11] However, these analogs were found to 
be associated with the blockade of the hERG (human Ether-
a-go-go Related Gene) channel, which is related to an 
augmented risk of cardiac arrhythmia. The basic nitrogen in 
the side chain at the 7 position was identified as responsible 
for the inhibition of the hERG channel, thus several 
derivatives bearing the piperazino moiety directly attached to 
the phenyl ring were prepared. All the synthesized 
compounds showed affinity in nanomolar or sub-nanomolar 
range with a low hERG inhibition. The most potent 
compound of the series has been the homologue of 
compound 176 (compound 177). [12]   
 Neustadt et al. investigated also the 2 position of the TP 
nucleus, by replacing the furyl group, which is a common 
structural feature of almost all A2A AR antagonists. 
Interestingly, 3-cyano-phenyl group maintains affinity and 
receptor selectivity (178, hA2A AR Ki= 0.7 nM, A1/A2A= 
1,071), but failed to show pronounced in vivo activity. [13] 
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 Kiowa Hakko Kogyo Co. designed several 7-carbamoyl 
derivatives of TPs and these compounds were found to be 
less potent than their corresponding amino derivatives, as 
observed comparing compound 179 (Figure 13, hA2A AR 
displ. at 0.1 µM = 65%) with compound 166 (hA2A AR Ki = 
1.8 nM). [72] Instead, a small alkyl moiety such an ethyl or 
Figure 12. TP derivatives as A2A AR antagonists: compounds 164-177. 
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an isopropyl (compound 180) gave potent A2A AR 
antagonists. [71] In addition, some 8-substituted derivatives 
were developed in this series, revealing that small a 
alkylamido group confers high potency at the A2A AR even 
when present at the 8 position, such as in the 8-(N-
ethyl)amido derivative 181, which displaced 96% of a 
specific radioligand for the A2A AR at a concentration of 0.1 
µM. [71]  
Recently, a novel series of TP substituted at both the 5 and 8 
position was developed and the derivatives were 
characterized at all the AR subtypes. [14] The introduction 
of an arylureido moiety at the 5 position (182) gave different 
results in terms of affinity and selectivity depending on the 
substitutions at the 8 position. The simultaneous presence at 
the 8 position of an ethoxycarbonyl (182) or a methyl 
carboxamido function led to compounds with quite good 
affinity and selectivity for the hA2A AR (e.g., compound 182: 
hA2A AR Ki = 4.82 nM; hA2A/hA3 = 0.01; hA1/hA2A = 66.8), 
whereas a bigger β-phenethylcarboxamido group or the 
replacement of arylureido group with a phenylacetamido 
group produced a decrease of affinity at the hA2A AR. A very 
different behavior was observed when alkylamino moieties 
were introduced at the 5 position of 8-ethoxycarbonyl-TP.  
In fact, a clear enhancement of affinity at the hA3 AR was 
observed for these compounds. Benzylamino moieties led to 
derivatives displaying good affinity at the hA3 AR but 
selectivity is still poor (e.g. compound 183, hA3 AR Ki = 10 
nM; hA1/hA3 = 94; hA2A/hA3 = 3.2). Better results in terms 
of both affinity and selectivity at the hA3 AR were obtained 
with small alkyl groups at the 5 position, such as for 
methylamino derivative (184) which showed a Ki value of 
4.14 nM at the hA3 AR and was 236- and 25-fold selective 
against A1 and A2A ARs, respectively. [14] 
The structure activity relationship of TP derivatives is 
summarized in Figure 14. 
4. PYRAZOLO[3,4-d]PYRIMIDINES 
 Over the years, several research groups have been 
interested in the development of pyrazolo[3,4-d]pyrimidines 
(PPs) as adenosine receptor antagonists. [15-21,79-82] This 
Figure 13. TP derivatives as A2A and A3 AR  antagonists: compounds 178-182 and 183-184, respectively. 
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can easily be attributed to the fact that PPs (4) are 
structurally very similar to the purine nucleus (185), whereas 
the imidazole ring is replaced by a pyrazole ring. In addition, 
the potent tricyclic adenosine receptor antagonists PTPs (1) 
are PP-fused derivatives, so PPs (4) can be considered as a 
structural simplification of this scaffold. (Figure 15)  
4.1. Chemistry 
 The most used starting materials for the synthesis of PPs 
are the 1-substituted-5-amino-1H-pyrazole-4-carbonitriles 
(7) or their corresponding regioisomers 3-amino-1-
substituted-1H-pyrazole-4-carbonitrile (17).  
These compounds were obtained as discussed in Section 2.1 
and their principal applications for the synthesis of PPs were 
shown in Scheme 18. The 4,6-dichloro-1-substituted-1H-
pyrazolo[3,4-d]pyrimidine (188) could be easily obtained by 
treatment of the corresponding di-hydroxy derivative (187) 
with phenylphosphoryl dichloride. Compound 187 was 
obtained by heating the 5-amino-1-substituted-1H-pyrazole-
4-carboxamide (186) with urea. The carboxamido group of 
compound 186 originated from the conversion of the cyano 
group of compound 7 in acidic conditions. [18,79] 
Alternatively, the reaction between compound 7 and 
potassium ethyl xanthogenate afforded the 4,6-dithiol-PP 
(189), which thiol groups could be successively alkylated 
(compounds 190 and 191). If the alkylation at the 4 position 
was performed using methyliodide, the resulting methylthio 
derivative could be used to introduce different amino 
moieties at the 4 position of the PP scaffold (compound 
192). [17,80] Finally, compound 7, by treatment with an 
alkyl- or aryl-isocyanate in the presence of a base, such as 
sodium methoxide or n-butyllithium, led to 5-substituted-
pyrazolo[3,4-d]pyrimidin-6(5H)-ones (194). This reaction 
occurred via cyclization of the corresponding 3-ureido 
derivative, which was confirmed by the isolation of 
derivative 193, obtained by addition of the isocyanate 
without the base. Compound 193 was then effectively 
converted in compound 194 using ammonium hydroxide. 
[15] 
 The 4,6-dichloro-PP (188) allows to introduce 
substitutions of different nature at the 4 and 6 positions of 
the PP scaffold. For example, the simple reaction between 
compound 188 and (ar)alkylamino derivatives led to the 
substitution of the chlorine atom at the 4 position which 
afforded compounds of general formula 195. Compounds 
195 were in turn converted to compounds 196 by treatment 
with sodium alkoxide at 90°C. [16] The presence of a 
halogen atom in compound 188 allows the application of 
carbon-carbon cross-coupling reactions, for example 
Gillepsie et al. have applied the Stille reaction to compound 
188 in order to obtain 4-aryl derivatives (197). Again, the 
second chlorine atom can be substituted by reacting 
compound 197 with various amines affording compounds of 
general formula 198 (Scheme 19). [18,79] 
Figure 15. PPs as AR antagonists. 
 
Figure 14.  Structure activity relationship of TP derivatives at ARs. 
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 PP derivatives were developed also starting from 6-
amino-4-chloro-PP (30) the synthesis of which is described 
in Section 2.1 (Scheme 4). Because compound 30 is 
unsubstituted on the pyrazole ring, the Stille reaction was 
made on the N-Boc protected derivative and the resulting 
compound was deprotected by hot dimethylamine. These 
reactions afforded compounds of general formula 199, which 
are functionalized on the pyrazole ring by alkylation or by 
reaction with the appropriated isocyanate, leading to 
compounds 200 and 201. Alternatively, alkylation on the 
pyrazole ring could be performed on compound 30 and, then, 
the aryl moiety introduced by Suzuki or Negishi coupling as 
shown in Scheme 20. The alkylation step afforded a mixture 
of N1 and N2 alkylated PP derivatives (202-203), which was 
used in the next step without purification, affording a 
mixture of compounds 204 and 205. [18,79] 
 Venkatesan et al. reported a synthetic approach to obtain 
directly compounds of general formula 203, starting from the 
appropriated 3-amino-1-substituted-1H-pyrazole-4-
carbonitrile (17). [20,21] As displayed in Scheme 21, the 
Scheme 18. Reagents: i: H2SO4 (aq), 60°C, 1h, R= CH2CH2Ph; ii: urea, neat, 180°C, 1h, R= CH2CH2Ph; iii: PhPOCl2, 165°C, 
16h, R= CH2CH2Ph; iv: Potassium ethyl xanthogenate, R = Ph; v: R1Br, pyr, rt, R = Ph, R1 = CH(alkyl)CONH2; vi: R2I, 
NaOH(aq), rt, R = Ph, R1 = CH(alkyl)CONH2, R2 = CH3; vii: NH2R4, EtOH, 110°C, sealed tube, 72h. R = Ph, R1 = 
CH(alkyl)CONH2, R4 = H, CH3; viii: R3NCO, DMF, 80°C, 24h, R = alkyl or aryl, R3 = CH3; ix: 30% NH4OH, DMF, rt, 24h; x: 
(method A) R3NCO, NaOCH3, DMF, 60°C, 12h or (method B) n-BuLi, THF, -70°C, R3NCO, 1h, -70°C rt, 1h, R = alkyl or 
aryl, R3 =alkyl or Ph. 
 
Scheme 19. Reagents: i: R1NH2, EtOH, rfx; ii: NaOR2, 90°C; iii: (tributylstannyl)R3, PdCl2(PPh3)2, DMF, rt, R3 = heteroaryl; 
iv: R4R5NH, NMP or iPrOH, , R4,R5 = alkyl, hydroxyalkyl. 
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carboxamide derivatives (206) were obtained by treatment of 
compound 17 with sulfuric acid (as reported in Scheme 18 
for the other pyrazole regioisomer). Further, the carboxamide 
derivatives (206) were refluxed with benzoylisothiocyanate 
in acetone, to obtain the benzoylthioureido derivatives (207). 
Treatment of 207 with methyl iodide in aqueous sodium 
hydroxide solution gave the corresponding 
carbamidothioates 208. The methylthio derivatives (208), by 
reaction with ammonia at 120°C, afforded the 
benzoylguanidino derivatives (209). Hydrolysis of the 
benzoyl guanidine derivatives under basic conditions allows 
the cyclization, affording the corresponding 6-amino-2-
Scheme 20. Reagents: i: (A) Boc2O, TEA, DMAP, DMF, rt, (B) tributylstannyl-aryl, PdCl2(PPh3)2, DMF, rt, (C) (CH3)2NH 
(aq), Δ; ii: NaH, DMF, 0°C, R1CH2Br, rt; iii: PhCH2NCO, DMAP, DMF, rt;  iv: NaH, DMF, BrR, 0°C to rt, R = 2-F-Bn; v: 
ArB(OH)2, Pd(PPh3)4, NaHCO3, THF, , or ArH, n-BuLi, THF, 1M ZnCl2, Pd(PPh3)4, -78°C to . 
 
Scheme 21. Reagents: i: conc. H2SO4, 0°C to rt, 5 h; ii: PhCONCS, acetone, rfx, 12 h; iii: CH3I, 0.1 N NaOH, rt, 3 h; iv: 2% aq 
NH3, DMF, 120°C, sealed tube, 3 h; v: 1N NaOH, rfx, 12 h; vi: POCl3, dimethylaniline, rfx, 24 h; vii: R1Cl, DIPEA, toluene, 
rfx, 24 h, R1= Ar or ArCH2; viii: NaCN, p-toluene sulfinate sodium, DMF, 80°C, 2 h; ix: K2CO3, 30% H2O2 (aq), rt, 1 h; x: 
EtOH, conc. H2SO4, rfx, 12 h. 
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alkyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-ones (210). 
Compounds 210 were further reacted with phosphoryl 
oxychloride in the presence of dimethylaniline under reflux 
condition to form the corresponding chloro analogs (203). 
Compound 212 was prepared by treating compound 203 with 
sodium cyanide in the presence of sodium p-toluene sulfinate 
as catalyst. The resulting 4-cyano-PP (212) was first 
hydrolyzed to 4-carboxamido-PP (213), using aqueous 
hydrogen peroxide and aqueous potassium carbonate, and 
then it was esterified to obtain the corresponding 4-
carboxylate-PP (214). Both compounds 203 and 214 were 
successively acylated at the free amino group at position 6 of 
the PP nucleus, by using the desired acylchlorides in the 
presence of a base (211, 215). [20,21] 
 Taliani et al. reported a series of 2-substituted-PP as A3 
AR antagonists. [19] As shown in Scheme 22, they used a 
very simple synthetic approach. Compound 17 was reacted 
with boiling formamide to afford the 6-unsubstituted-2-
substituted-2H-pyrazolo[3,4-d]pyrimidin-4-amine (216, 
R1=H). The 6-phenyl-PP derivative (216, R1=Ph) was 
obtained by reaction with benzonitrile in the presence of 
potassium tert-butoxide and under microwave irradiation. 
Compounds 216 were converted to the corresponding 4-
arylamido and 4-arylureido derivatives (217) by treatment 
with the appropriate acylchloride in the presence of 
triethylamine or with the appropriate isocyanate, 
respectively. [19]rnold et al. patented a few pyrazolo[3,4-
d]pyrimidin-4(5H)-one (219) and pyrazolo[3,4-d]pyrimidin-
4(5H)-thione derivatives (220) as anticonvulsive, antiallergic 
and antiasthmatic agents targeting ARs. [81] Scheme 23 
shows that 4-thione derivatives (220) were obtained by 
reaction of compounds of general formula 219 with 
phosphorous pentasulfide in hot pyridine or with 2,4-bis(4-
methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide 
in xylene at reflux. Analogously to that reported by Taliani 
et al., compounds 219 were obtained refluxing compounds 
of general formula 218 in formamide. The presence of an 
amido or ester moieties, instead of a cyano group (as in 
compound 17) at the 4 position of the pyrazole 218, led to 
the introduction of the oxo group (compound 219), instead of 
the amino group (216) at the 4 position of the PP scaffold. 
[81] 
Scheme 22. Reagents: i: (for R1 = Ph) PhCN, t-BuOK, MW, or (for R1 = H) boiling NH2CHO, 12 h; ii: R2XCOCl, TEA, MW 
or R2NCO, MW, R2 = aryl. 
 
Scheme 23. Reagents: i: NH2CHO, 100-200°C, 8-16h, X = NH2, O-alkyl; ii: P2S5, pyr, 80-115°C, 4-8h or 2,4-bis(4-
methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide, xylene, rfx, 8-24h. 
 
Scheme 24. Reagents: i: RNHNH2, EtOH, rfx, 15h; ii: R1NCO, TEA, CHCl3, sealed tube, 120°C, 62h; iii: 2N NaOH, rfx, 4 
min; iv: NaH, DMF, R2I, 3h, rt. 
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 Peet et al. synthesized PP derivatives very similar to 
xanthines (Scheme 24). They obtained the desired pyrazoles 
(222) by reacting ethyl(ethoxymethylene)cyanoacetate (221) 
with the appropriated substituted-hydrazine. Aminopyrazoles 
(222), when treated with excess methylisocyanate, gave the 
bisureas of general formula 223. Cyclization of compounds 
223 with aqueous sodium hydroxide gave the 4,6-dione-PPs 
(224). Further alkylation of compounds 224 with alkyliodide 
and sodium hydride in dimethylformamide gave a mixture of 
compounds 225 and 226, easily separated by flash 
chromatography. [16] 
 Finally, Paira et al. developed a series of chelating 4-
imino-(2-substituted)-2H-pyrazolo[3,4-d]-pyrimidines to 
form an organoruthenium A3 AR antagonist which was 
structurally related to PTP. 3-Amino-4-pyrazolecarbonitriles 
(17) were transformed into their corresponding 5-amino-4-
imino-2-substitutedamino-4,5-dihydro-2H-pyrazolo[3,4-
d]pyrimidin-6(7H)-one (227) through a reaction with 
hydrazine derivatives in EtOH at 80°C. Furthermore, 
treatment of compound 17 with ethyl chloroformate afforded 
carbamates (228), which in turn were treated with 
benzhydrazide derivatives in EtOH at 80°C to afford the N-
(4-imino-2-methyl-6-oxo-6,7-dihydro-2H-pyrazolo[3,4-
d]pyrimidin-5(4H)-yl)benzamide (227, R1=PhCO). Pyrazole 
17 was also treated directly with triethyl orthoformate under 
Figure 16. PP derivatives as A1 AR antagonists. 
 
Scheme 25. Reagents: i: R1NHNH2, EtOH, 80°C, 6h, R= 
CH3, EtPh, PrPh, R1 = H, Ph; ii: ClCOOEt, pyr, DMAP, 0°C 
to rt, 12h, R = CH3, EtPh, PrPh; iii: R1NHNH2, EtOH, 80°C, 
6h, R = CH3, R1 = PhCO; iv: CH(OEt)3, rfx, 6h, R = CH3; v: 
NH2NH2.H2O, EtOH, 0°C to rt, 3h, R = CH3. 
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reflux to give the imidate derivatives (229), which were 
further cyclized with hydrazine hydrate in ethanol to the 
corresponding PP compounds with general formula 230. 
(Scheme 25) [82] 
4.2. Structure activity relationship 
A1 AR antagonists.  
In a work aimed to develop conformationally restrained 
(phenylisopropyl)amino-substituted-PPs, Peet and coworkers 
explored the effect of substituents at the 4 and 6 position of 
the PP scaffold. [16] In particular, they observed that 
compound 231, which is a PP-4,6-dione, showed an IC50 of 
33 μM at the rA1 AR, whereas the alkylation at the 6 position 
(concomitantly to the removal of substituent at N7-position) 
improved the affinity, such as for compound 232 that 
displayed an about 7-fold increased affinity at the rA1 AR 
(IC50= 4.8 μM). Interestingly, compound 233, which bears a 
second substitution at the 4 position with an amino moiety, 
showed a greater affinity at the A1 AR subtype than 
compounds 231 and 232 (Figure 16). Instead, Harden and 
coworkers performed a preliminary investigation on N1- and 
N5-substituted PPs. The series involved the variation of the 
substituent at the N1-position with small alkyl groups, 
phenyl or substituted phenyl moieties (e.g. halogen, NO2 and 
NH2 at m, o and p positions of the phenyl ring), and the 
variation of the substituent at the N5-position with small 
alkyl moieties or phenyl group.  
Binding data at the A1 AR demonstrated that compounds 
possessing substituted aromatic groups showed greater 
affinity than those with alkyl groups at the N1-position. 
Additionally, the investigation on the substituted phenyl 
moieties showed that chlorine produced a greater response 
than bromine and fluorine substitutions, whereas nitro or 
amine substitutions were inactive at a concentration of 20 
μM. Secondly, substitution of the aromatic group in the meta 
position gave better affinity values at the rA1 AR (e.g. 
compound 234, displ. at 20 μM = 53%, IC50 = 16.5 μM) than 
orto or para substitutions (e.g. compound 235, displ. at 20 
μM = 7%). In regard to substitutions at the 5 position, an 
alkyl moiety showed greater AR affinity than the aromatic 
group. The most active compound of the series was 
compound 236 which displayed an IC50 of 9.6 μM. Even 
though an improvement of affinity was achieved, both 
affinity and selectivity of these compounds were poor. 
 In 1984, Davies et al. developed a series of PPs as 
purinergic receptor antagonists, in particular, as A1 AR 
antagonists. [82] The lead compound, 2,2'-((1-phenyl-1H-
pyrazolo[3,4-d]pyrimidine-4,6-
diyl)bis(sulfanediyl))dipropanamide (237), showed an 
affinity of 370 nM at the A1 AR. Compound 237 represented 
the starting point to perform a structural optimization with 
the aim to improve binding affinity at the A1 AR. [17] In 
fact, compound 237 was modified at the 4 position with 
mercapto, methylthio, and amino groups in order to 
investigate the hydrogen-bonding and steric tolerance at this 
position. At the 6 position of the PP scaffold, the 2-
mercaptoalkylamide chain was maintained but varying the 
length of the alkyl chain. [17] From the binding data at rA1 
AR, it was found that the Ki value depended principally on 
the substituent present at the 4 position and decreased in the 
order SH>>SCH3>NH2≥NHCH3, with compound 238 being 
the most potent of the series at the rA1 AR (rA1AR Ki = 
0.745 nM). Moreover, alkyl chain at α position of the sulfur 
atom at the 6 position of PP was found to influence affinity 
at the A1 AR. In this case, Ki value decreased in the order i-
Pr>>Et>Pr>Bu, thus indicating that a branched alkyl moiety 
was unfavorable in terms of affinity, probably due to its 
steric hindrance. Compounds were tested also at the rA2A AR 
and binding data suggests that 4-methylthyio compounds 
were the most promising compounds because they showed 
nanomolar affinity at the rA1 AR, with high levels of 
selectivity over rA2A AR (e.g. compound 239, rA1AR Ki = 
6.81 nM, rA2A/rA1 > 5,900). [17]  
A2A AR antagonists  
 PPs were explored by Gillespie and collaborators as A2A 
AR antagonists [18,79] for their evaluation in the treatment 
of PD. The 4-(furan-2-yl)PP (240) was found to possess a Ki 
of 48 nM at the hA2A AR and was 13-fold selective over A1 
AR subtype. (Figure 17) The introduction of a benzyl moiety 
at the 1 position of the PP ring (241) increased affinity at the 
A2A AR (compound 241, hA2A AR Ki = 3 nM). Instead, both 
substitution of the phenyl ring with various heterocycles and 
the extension of the linker between phenyl and PP (from 1 to 
2 or 3 methylene groups), did not improve affinity. 
Successively, the effects of substitution around the phenyl 
ring were explored. Binding data demonstrated that 
substitution on the meta-position (see compound 242, hA2A 
Figure 17. PP derivatives as A2A AR antagonists. 
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AR Ki = 1 nM) of phenyl ring was preferred to ortho- and 
para- substitutions (e.g. compound 243, hA2A AR Ki = 9 
nM), which generally decreased affinity compared to parent 
compound 241. Finally, furyl moiety at the 4 position of PP 
was replaced by other aromatic rings, but all the compounds 
displayed a reduced affinity at the A2A AR, such as 4-
pyrazol-3-yl compound 244 (hA2A AR Ki = 16 nM). [18,79] 
A3 AR antagonists 
 The first report on development of A3 AR antagonists 
with a PP nucleus came from Arnold and its coworkers, 
which focused on a series of pyrazolo[3,4-d]pyrimidin-
4(5H)-ones and pyrazolo[3,4-d]pyrimidine-4(5H)-thiones. 
These compounds bear a substituted benzyl moiety at the 2 
position of PP, thus on the 2 position of the pyrazole ring. 
Substitutions on the phenyl ring were almost limited to the 
meta position. Best results were obtained with halogen 
substituents, in particular with 2-bromo substituent, both in 
4-one (compound 245, hA3 AR Ki = 430 nM) and 4-thione 
series (compound 246, hA3 AR Ki = 340 nM). Taliani et al. 
developed a new series of PP based on their previous results 
on imidazole[1,2-a][1,3,5]triazines, which are isosters of PP. 
[19] The imidazole-[1,2-a][1,3,5]triazine 247 showed high 
affinity at the hA3 AR and quite good selectivity over A1 and 
A2A ARs, however its corresponding PP derivative (248) 
showed higher affinity at the hA3 AR subtype. For this 
reason new PP derivatives were synthesized in order to 
explore the SAR of these compounds at the hA3 AR. Binding 
affinity results suggested that phenyl ring at the 6 position 
was a key feature for recognition at the ARs, since its 
removal (e.g. compound 249, hA3 AR Ki > 1,000 nM) led to 
poor affinity to all the ARs. At the 2 position, both methyl 
and benzyl groups are tolerated, while a phenylethyl moiety 
decreased affinity at the hA3 AR. Interestingly, compounds 
bearing a free amino moiety at the 4 position are poorly 
active at the hA3 AR and also totally unselective over the 
other AR subtypes, while the substitution at the 4 position 
with arylamides or arylureas enhanced both affinity and 
selectivity at the hA3 AR. The best compound of the series is 
compound 250, which showed a hA3 Ki value of 0.18 nM. 
Figure 18. PP derivatives as A3 AR antagonists. 
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Compounds 248 and 250 were subsequently tested on human 
glioma U87MG cells, and they were able to counteract the 
proliferation of glioma cells mediated by A3 AR agonists. 
[19] 
 Recently, Venkatesan et al. developed a series of 4-
chloro-PP as a simplification of the PTP scaffold, which was 
well-known to afford potent hA3 AR antagonists (see Section 
2.2). [20] The series investigated both 1 and 6 positions of 
the PP nucleus. Compounds were active in the micromolar 
range at the hA3 AR and almost all are completely 
unselective. On the contrary, when the chloro moiety at the 4 
position was substituted with ethyl carboxylate group, an 
improvement of affinity and especially of selectivity was 
observed, as clearly shown in Figure 18 for compound 251 
(hA3 AR Ki = 900 nM, A1/A3 = 111, A2A/A3 = 111). [20] A 
further investigation on these new compounds revealed that 
neopentyl moiety at the 2 position is preferred over other 
alkyl of arylalkyl goups. In addition, replacement of the 
benzoyl group with a phenylacetyl moiety led to a complete 
loss of selectivity (252). [21] 
Figure 19 depicts the SAR analysis of PP compounds at 
ARs. 
5. MOLECULAR MODELING STUDIES AT THE 
ADENOSINE RECEPTORS 
5.1 Homology Modelling 
 Very recently, several X-ray structures of the hA2A AR in 
complex with agonists and antagonists have become 
available. [83-90] These structures represent valuable 
starting points for structure-based drug design approaches. 
[91] Moreover, they can serve as templates to gather 
structural information on the other ARs subtypes by means 
of homology modelling. The success of the homology 
modelling approach depends upon at least two key factors: 
the sequence identity and the sequence alignment between 
the template and the target structure. In the homology 
modeling of ARs, the sequence alignment is guided by the 
Figure 20. Overview of the conserved residues (sticks 
representation) at the hA2A AR that guide the sequence 
alignment for the construction of ARs models. 
 
Figure 19. Structure activity relationship of PP derivatives at ARs. 
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most conserved residues in each transmembrane ™ domain, 
i.e. the TM.50 residue used as reference in the Ballesteros 
and Weinstein nomenclature system for class A GPCRs 
[92,93], such as: Asn1.50, Asp2.50, Arg3.50, Trp4.50, 
Pro5.50, Pro6.50 and Pro7.50 in TM1-7, respectively (Figure 
20). As far as the sequence identity is concerned, the hA2A 
AR shares 55.9%, 67.4%, and 47.7% sequence identity with 
the hA1 AR, the hA2B AR, and the hA3 AR, respectively.  
 The growing interest in the modeling of GPCRs has 
prompted the scientific community to release several ad hoc 
web services [94-98] among which “Adenosiland”, a 
platform entirely dedicated to ARs. [99] In Adenosiland, 
homology models for all the cloned ARs are freely available. 
These models were derived from a homology modeling 
protocol followed by 20 ns of molecular dynamics (MD) 
simulations in near-native environment (solvated lipid 
bilayer embedded receptor). The so refined structures 
represent a structural alternative to homology models. A tool 
to guide the user in the selection of an appropriate template 
to build ARs homology model has also been implemented. 
[100] The models deposited in Adenosiland as well as the 
template searching facility have been exploited to gather 
macromolecular starting points for the rationalization of 
SARs of different series of ARs antagonists, such as PTP 
and TP. [14,42] 
5.2 Docking  
 Provided that a three-dimensional structure - either from 
experimental data or computationally derived - is available, 
molecular docking is one of the most widely used structure 
based drug design techniques. The analysis of docking poses 
represents a helpful tool to rationalize SARs. With respect to 
ARs binders, docking studies have been extensively used to 
elucidate the molecular signatures favoring or affecting the 
binding of antagonists at the hA2A and the hA3 ARs. In some 
cases, docking studies helped in explaining the selectivity 
profiles exhibited by the most promising synthetized 
derivatives. Moreover, the analysis of the docking results 
allows to speculate on the most favorable orientations of the 
substituents on the scaffolds, thus providing rationale 
suggestions for further derivatizations. 
 With regard to this, we have recently reported on the 
analysis of the 5 position of the PTP scaffold at the hA3 AR. 
[42] In particular, we have evidenced the possibility of the 
scaffold to adopt two different orientations in the binding 
site according to the nature of the substituent linked to the 
N5 atom that gives rise to the interaction with different TM 
domains (Figure 21).  Compounds bearing small alkyl and 
cycloalkyl groups and polar chains prefer a binding mode 
(BM1, vertical arrow) that exposes the substituent to the 
extracellular side and envisages the interaction with TM6, 
TM7, and EL2 (extracellular loop 2). Ligands bearing 
aromatic rings, bulky substituents as well as those with the 
double substitution at the N5 atom, preferentially adopt a 
binding mode (BM2, horizontal arrow) that points the 
Figure 21. Hypothetical binding modes of example PTP compounds exhibiting BM1 (A) and BM2 (B) inside the hA3 AR 
binding site. Poses are viewed from the membrane side facing TM6, TM7, and TM1 with the view of TM7 partially omitted to 
aid visualization. The side chains of Asn250 (6.55) and Phe168 (EL2) are represented in ball and stick. Hydrogen bond 
interactions are highlighted as dashed lines, whereas the side chains of residues interacting with the ligand through 
hydrophobic contacts are displayed as surfaces. An arrow indicating the directionality of the substituent at the PTP N5 position 
is shown. (C) Schematic representation of the hA3 AR embedded in a solvated lipid bilayer simulating the cell membrane. The 
side chains of residues interacting through hydrophobic contacts are displayed as ball and sticks, for BM1 and BM2. Side 
chains of Asn250 (6.55), Phe168 (EL2), and Trp243 (6.48) are represented in gray ball and stick. Hydrogen atoms are omitted. 
Readopted from ref [42].  
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substituent inside the binding cavity interacting with TM2, 
TM3, and EL2.  
 The possibility for a scaffold to adopt different binding 
modes depending on the nature and the steric hindrance of 
the substituents has also emerged through the analysis of the 
docking poses at the hA3 AR of a series of 5,8 disubstituted-
TP. (Figure 22) [14] Derivatives bearing small alkyl and 
cycloalkyl groups interact with Asn250 (6.55) through the 
ethoxycarbonyl group at the 8 position, by pointing the furan 
ring toward TM2 and exposing the alkyl group to the 
solvent. Compounds bearing branched chains and benzyl 
groups interact with Ans250 (6.55) with the N4 of the 
triazole ring, with the furan ring solvent exposed and the 
alkyl/benzyl group projected toward TM2. 
5.3 Molecular Dynamics  
 Besides molecular docking, MD is a powerful tool 
nowadays largely used in medicinal chemistry and drug 
discovery. [101] With respect to the static analysis proposed 
by the docking solutions, MD simulations enable to take into 
account also the flexibility of protein side chains and the 
interactions mediated by water molecules. The description of 
these two fundamental aspects in ligand binding is still 
challenging to be depicted by conventional docking 
approaches. [102] A strategy to follow the dynamics of 
ligand-receptor interaction is to compute the so-called the 
“dynamic scoring function” (DSF), [103] i.e. the cumulative 
sum of electrostatic and hydrophobic contributions to the 
interaction energy computed between the ligand and selected 
residues surrounding the binding site over time. This feature 
has been introduced and exploited to support an apparently 
less plausible binding mode of a series of 5-
alkylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines at 
the hA3 AR. [42] In particular, the two different binding 
modes described above (Figure 20) have been validated 
through 60 ns of membrane MD simulations. 
CONCLUSIONS 
 Adenosine receptor antagonists could be useful for the 
treatment of hypertension, heart and kidney failure, 
inflammation, neurodegenerative disorders (e.g. PD), 
asthma, COPD, cancer and glaucoma, depending on the 
targeted AR subtype. Therefore, the development of 
antagonists potent and selective for a specific AR subtype is 
of remarkable importance. PTP represent one of the most 
important scaffolds among adenosine receptor antagonists. 
Synthesis of the PTP scaffold was optimized over the years, 
allowing the development of extended series of derivatives 
which led to acquisition of a good SAR profile, especially 
towards the A2A and A3 AR subtypes. Preladenant (2) is a 
promising PTP derivative that reached phase III clinical 
trials for the treatment of PD. Unfortunately it failed at this 
stage of clinical research but the reasons are still unclear. 
Nevertheless, PTP derivatives are tricyclic compounds with 
a high molecular weight which exhibit limitations such as 
poor aqueous solubility and difficult synthetic preparation. 
TP and PP are bicyclic scaffolds which could be considered 
as simplified analogs of PTP, possessing a lower molecular 
weight and thus probably showing better drug-like properties 
than PTP. TPs were principally developed by industries to 
obtain A2A AR antagonists. SAR of these compounds was 
not fully explored, thus, further investigations on this 
scaffold are needed. Instead, PPs were studied almost 
exclusively by academia, which apply very different 
approaches to find potent AR antagonists. The high 
structural variability of these compounds and the different 
biological assays used in the various studies, make difficult 
to obtain a good SAR profile of these derivatives. Molecular 
modeling studies helped to rationalize the obtained 
experimental binding data and also to design new optimized 
derivatives. Both docking and molecular dynamics are 
powerful tools largely used in medicinal chemistry and drug 
discovery. Indeed, optimization of the PTP derivatives, and 
recently also optimization of the TP and PP derivatives, as 
AR antagonists were strongly supported by molecular 
modeling studies. 
 
LIST OF ABBREVIATIONS 
AC, adenylyl cyclase;  
AR, adenosine receptor;  
BM, binding mode;  
Boc, tert-butyloxycarbonyl;  
Figure 22. Hypothetical binding modes of example TP 
compounds exhibiting BM1 (A) and BM2 (B) inside the hA3 
AR binding site. Poses are viewed from the membrane side 
facing TM6, TM7, and TM1, hydrogen bonds are highlighted 
as dashed lines, and side chains of Asn250 (6.55) and Phe168 
(EL2) are represented in balls and sticks. An arrow indicating 
the directionality of the furan ring is shown. Readopted from 
ref. [14]. 
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BSA, N,O-bis(trimethylsilyl) acetamide;  
cAMP, cyclic adenosine monophosphate;  
CNS, central nervous system;  
COPD, chronic obstructive pulmonary disease;  
CSA, camphorsulfonic acid;  
DBU, 1,5-diazabiciclo(5.4.0)undec-5-ene;  
DCM, dichloromethane;  
DEAD, diethyl azodicarboxylate;  
DIBAL, diisobutylaluminium hydride;  
DIPEA, N,N-diisopropylethylamine;  
DMAP, 4-dimethylaminopyridine;  
DMF, N,N-dimethylformamide;  
DMSO, dimethylsulfoxide;  
DSF, dynamic scoring function;  
EDCI, N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride;  
EGME, ethylene glycol monomethyl ether (2-
methoxyethanol);  
EL, extracellular loop;  
FDA, food and drug administration;  
FST, forced swim test; 
GPCR, G protein-coupled receptor;  
hERG, human Ether-à-go-go-Related Gene potassium 
channel;  
HMDS, hexamethyldisilazane;  
HMDSO, hexamethyldisiloxane;  
HOBt, hydroxybenzotriazole;  
IC50, half maximal inhibitory concentration; 
Ki, inhibition constant;  
MD, molecular dynamics;  
MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine;  
NMM, N-methylmorpholine;  
NMP, 1-methyl-2-pyrrolidinone;  
PCC, pyridinium chlorochromate;  
PD, Parkinson’s disease;  
PP, pyrazolo[3,4-d]pyrimidine;  
PPSE, polyphosphoric acid trimethyl silyl ester;  
PTP, pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine;  
SAR, structure activity relationship;  
TEA, triethylamine;  
TFA, trifluoroacetic acid; 
THF, tetrahydrofuran;  
TM, transmembrane;  
TP, [1,2,4]triazolo[1,5-c]pyrimidine;  
TST, tail suspension test. 
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